

**2022 ISV ANNUAL CONGRESS ORAL PROGRAM**  
**SUNDAY 18 SEPTEMBER 2022**

<b>08:00-10:00</b>	<b>REGISTRATION</b>
<b>08:00-10:00</b>	<b>WELCOME COFFEE</b> <span style="float: right;"><b>Sponsored by EuBiologics Co.</b></span>
<b>10:00-10:10</b>	<b>ISV CONGRESS CO-CHAIRS:</b> Joon Haeng Rhee, <i>Chonnam National University</i> ; Manon Cox, <i>NextWaveBio</i> ; Gary Kobinger, <i>University of Texas Medical Branch (UTMB)</i> <b>OPENING REMARKS -</b> Denise Doolan, <i>ISV President</i>
<b>10:10-11:55</b>	<b>OPENING SESSION: HOT TOPICS IN 21<sup>st</sup> CENTURY VACCINES</b> <b>SESSION CHAIRS: TBC</b>
<b>10:10-10:45</b>	<b>KEYNOTE SPEAKER -</b> Bali Pulendran, <i>Stanford University</i> <b>Systems Vaccinology</b>
<b>10:45-11:20</b>	<b>KEYNOTE SPEAKER -</b> Ann Ginsberg, <i>Bill &amp; Melinda Gates Foundation</i> <b>End-to-End TB Vaccine Development to End TB</b>
<b>11:20-11:55</b>	<b>KEYNOTE SPEAKER -</b> Hiroshi Kiyono, <i>University of Tokyo</i> <b>Mucosal Vaccine: Bringing the Old Wisdom to Reality</b>
<b>12:00-13:30</b>	<b>LUNCH</b> <span style="float: right;"><b>Sponsored by VGXI, Inc.</b></span>
<b>13:30-15:20</b>	<b>PLENARY SESSION 1: COVID-19 VACCINES PART 1</b> <b>SESSION CHAIRS: TBC</b>
<b>13:30-13:55</b>	<b>Vectored Viral Vaccine Candidates for SARS-CoV-2</b> Amy Espeseth, <i>Merck</i>
<b>13:55-14:20</b>	<b>Differentiation of Memory T Cells Elicited by COVID-19 Vaccines</b> Eui-Cheol Shin, <i>Korea Advanced Institute of Science and Technology (KAIST)</i>
<b>14:20-14:35</b>	<b>What Vaccine-Induced Immune Responses Control Breakthrough COVID-19?</b> Stephen Kent, <i>University of Melbourne</i>
<b>14:35-14:50</b>	<b>Next Generation Multivalent COVID-19 DNA Vaccine</b> Makutiro Masavuli, <i>The University of Adelaide</i>
<b>14:50-15:05</b>	<b>Elicitation of Long-Lived Plasma Cells Following SARS-CoV-2 Spike Vaccination</b> Madhu Prabhakaran, <i>Vaccine Research Center, NIAID, National Institutes of Health</i>
<b>15:05-15:20</b>	<b>Robust Immunogenicity and Full Efficacy Against SARS-CoV-2 in Mice, Hamsters and Rhesus macaques of a COVID-19 Vaccine Candidate Based on an MVA Vector Expressing the SARS-CoV-2 S Protein</b> Juan García-Arriaza, <i>Centro Nacional de Biotecnología</i>
<b>15:30-16:00</b>	<b>COFFEE BREAK</b> <span style="float: right;"><b>Sponsored by AstraZeneca</b></span>
<b>16:00-17:50</b>	<b>PLENARY SESSION 2: VACCINE DESIGN AND ADJUVANT</b> <b>SESSION CHAIRS: TBC</b>
<b>16:00-16:25</b>	<b>Particulate Adjuvant Strategies for Cancer Vaccines</b> Ed Lavelle, <i>Trinity College Dublin</i>
<b>16:25-16:50</b>	<b>Vaccine Adjuvant and Production Technologies and Biomanufacturing Resilience in Canada</b> Lakshmi Krishnan, <i>National Research Council Canada</i>
<b>16:50-17:05</b>	<b>A Novel Draining Lymph Node Targeting CpG Oligonucleotide, S-540956 is a Potent Adjuvant When Used with HSV-2 Glycoprotein D and Controls Recurrent Genital Herpes</b> Sita Awasthi, <i>University of Pennsylvania</i>
<b>17:05-17:20</b>	<b>Deimmunized Flagellin as a Mucosal Vaccine Adjuvant</b> Koemchhoy Khim, <i>Chonnam National University</i>
<b>17:20-17:35</b>	<b>The Novel Adjuvant, ADA-1, Restores Age-Associated Defects in the Adaptive Immune Response to Clostridioides Difficile Infection and Vaccination in an Aging Mouse Model</b> Michele Kutzler, <i>Drexel University</i>
<b>17:35-17:50</b>	<b>In Vivo Delivery of Engineered Synthetic DNA-Encoded SARS-CoV-2 Monoclonal Antibodies and Preventative Efficacy in Non-Human Primates</b> Amy Patel, <i>The Wistar Institute</i>
<b>18:00-19:00</b>	<b>POSTER SESSION # 1</b>
<b>18:00-20:00</b>	<b>WELCOME RECEPTION</b> <span style="float: right;"><b>Sponsored by EpiVax</b></span>

<b>MONDAY 19 SEPTEMBER 2022</b>		
<b>08:00-08:30</b>	<b>MORNING COFFEE</b>	<b>Sponsored by GSK</b>
<b>08:30-09:55</b>	<b>PLENARY SESSION 3: VACCINES ON THE HORIZON</b> <b>SESSION CHAIRS: TBC</b>	<b>Sponsored by Sanofi Pasteur</b>
<b>08:30-09:00</b>	<b>The Evolution of Vaccinology and the Utility of Human Challenges (Pre-Recorded)</b> Stanley Plotkin, <i>Vaxxconsult</i>	
<b>09:00-09:25</b>	<b>mRNA Vaccines (R)Evolution – Myths and Realities</b> Jean-Francois Toussaint, <i>Sanofi Pasteur, France</i>	
<b>09:25-09:40</b>	<b>Interim Analysis of a Phase 1/2 Randomized Clinical Trial on the Safety, Reactogenicity, and Immunogenicity of a Quadrivalent, mRNA-Based Seasonal Influenza Vaccine (mRNA-1010) in Healthy Adults</b> Raffael Nachbagauer, <i>Moderna, Inc.</i>	
<b>09:40 -09:55</b>	<b>Development of a Flagellin-Adjuvanted Anti-Tauopathy Vaccination Strategy Targeting Pathologic Conformation</b> Sao Puth, <i>Chonnam National University</i>	
<b>10:00-10:30</b>	<b>COFFEE BREAK</b>	<b>Sponsored by SK Bioscience</b>
<b>10:30-12:20</b>	<b>CONCURRENT SESSION 1</b> <b>COVID-19 VACCINES PART 2</b> <b>SESSION CHAIRS: TBC</b>	<b>CONCURRENT SESSION 2</b> <b>GLOBAL HEALTH AND VACCINES</b> <b>SESSION CHAIRS: TBC</b>
<b>10:30 -10:55</b>	<b>SARS-CoV-2 Biology and Countermeasure Development</b> Pei-Yong Shi, <i>University of Texas Medical Branch (UTMB)</i>	<b>The mRNA Hub Technology Transfer Programme: Creating a Sustainable Platform for Vaccine Innovation in LMICs</b> Petro Terblanche, <i>Afrigen Biologics &amp; Vaccines</i>
<b>10:55-11:20</b>	<b>Development of a SARS-CoV-2 Vaccine Candidate Using the Papaya Mosaic Virus (PapMV) Nanoparticle Vaccine Platform</b> Denis Leclerc, <i>Université Laval</i>	<b>Strategies for Industrial Production of mRNA Vaccines in South America</b> Analia Acebal, <i>Sinergium Biotech</i>
<b>11:20-11:35</b>	<b>ACM Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine</b> Jiang Hang Lam, <i>ACM Biolabs Pte Ltd</i>	<b>Progress of Clinical Development of a Live-Attenuated Single Shot Chikungunya Vaccine Candidate</b> Susanne Eder-Lingelbach, <i>Valneva Austria</i>
<b>11:35-11:50</b>	<b>An Exosome-Based Pan Beta Coronavirus Vaccine</b> Timothy Soos, <i>Codiak BioSciences</i>	<b>T Cell Vaccines Against Zika Virus</b> Branka Grubor-Bauk, <i>University of Adelaide</i>
<b>11:50-12:05</b>	<b>A Protein/Peptide Vaccine UB-612 Elicits Broadly Neutralizing Antibodies Against Multiple Variants and Protects Mice and Non-Human Primates Against SARS-CoV-2</b> Shixia Wang, <i>Vaxxinity Inc.</i>	<b>Immunogenicity and Efficacy in Rodents and Non-Human Primates of a Pair of Two Live-Attenuated Flavivirus-Vectored Vaccine Candidates with Dual Rabies/Yellow Fever, or Rabies/Japanese Encephalitis Activity</b> Lorena Sanchez Felipe, <i>KU Leuven</i>
<b>12:05-12:20</b>	<b>Intranasal Administration of a Live-Attenuated Recombinant Newcastle Disease Virus Expressing the SARS-CoV-2 Spike Protein Induces High Neutralizing Antibody Levels and Protects from Experimental SARS-CoV-2 Infection in Hamsters</b> Nora Gerhards, <i>Wageningen Bioveterinary Research</i>	<b>Snail Fever (Schistosomiasis) Vaccine: 30 Years of a Bumpy Ride at a Snail's Pace</b> Afzal Siddiqui, <i>Texas Tech University Health Sciences Center</i>
<b>12:30-14:00</b>	<b>LUNCH</b>	<b>Sponsored by CanSino Biologics</b>
<b>13:30-14:30</b>	<b>ISV ANNUAL GENERAL MEETING</b>	
<b>14:00-15:30</b>	<b>POSTER SESSION # 2</b>	
<b>15:00-15:30</b>	<b>COFFEE BREAK</b>	<b>Sponsored by BioNTech</b>

<b>15:30-17:35</b>	<b>PLENARY SESSION 4: VACCINE DEVELOPMENT &amp; BIOMANUFACTURING LANDSCAPE IN CANADA</b>
<b>15:30-15:35</b>	<b>Session Introduction</b> Lakshmi Krishnan, <i>National Research Council Canada</i>
<b>15:35-16:00</b>	<b>Development of a Plant-Based Virus-Like Particle Vaccine Against COVID-19</b> Marc-André D'Aoust, <i>Medicago</i>
<b>16:00-16:25</b>	<b>Canadian COVID-19 Vaccine Candidates and Programs - Experience of the Clinical Trials Network of the Canadian Immunization Research Network</b> Joanne Langley, <i>Dalhousie University</i>
<b>16:25-16:50</b>	<b>Title TBC</b> Michael Rosu-Myles, <i>Health Canada</i>
<b>16:50-17:05</b>	<b>A DNA Vaccine Against Hyalomma Tick Infestation Protects Sheep Against Multiple Human Tick-Borne Viruses</b> Hugues Fausther-Bovendo, <i>Global Urgent and Advanced Research and Development (GUARD)</i>
<b>17:05-17:20</b>	<b>Breast Cancer Immunopeptidomes Reveal a Large Number of Targetable Tumor Antigens</b> Eralda Kina, <i>University of Montreal</i>
<b>17:20-17:35</b>	<b>Insights from Industry Collaboration in COVID-19 Vaccine Pharmacovigilance- One Manufacturer's Experience"</b> Jamie Wilkins, <i>Pfizer, Inc.</i>
<b>18:30-22:00</b>	<b>GALA DINNER</b> <b>*TICKETS REQUIRED*</b>

**Continue to Next Page**

## TUESDAY 20 SEPTEMBER 2022

<b>08:00-09:00</b>	<b>MORNING COFFEE</b>		<b>Sponsored by Pfizer</b>
<b>08:15-09:00</b>	<b>EDUCATIONAL BREAKOUT SESSION</b>		
<b>09:00-10:20</b>	<b>PLENARY SESSION 5: VACCINES AND ANIMALS</b> SESSION CHAIRS: <i>TBC</i>		
<b>09:00-09:25</b>	<b>Vaccination for the Prevention and Control of Emerging Infectious Diseases in Animals</b> <i>Mahesh Kumar, Zoetis</i>		
<b>09:25-09:50</b>	<b>One Health</b> <i>TBC</i>		
<b>09:50-10:05</b>	<b>Next Generation Monkeypox Vaccine Based on Development of an Efficacious T Cell-Directed Smallpox Vaccine Using a Genomes-to-Vaccine Strategy</b> <i>Anne De Groot, EpiVax, Inc.</i>		
<b>10:05-10:20</b>	<b>mRNA Vaccines Against Andes Virus: Comparison of Modified Versus Non-Modified Nucleoside-Based Platforms</b> <i>Alexander Bukreyev, University of Texas Medical Branch (UTMB)</i>		
<b>10:30-11:00</b>	<b>COFFEE BREAK</b>		<b>Sponsored by Novavax</b>
<b>11:00-12:25</b>	<b>CONCURRENT SESSION 3</b> <b>HIV VACCINES</b> SESSION CHAIRS: <i>TBC</i>	<b>CONCURRENT SESSION 4</b> <b>MANUFACTURING AND EVALUATION</b> SESSION CHAIRS: <i>TBC</i>	
<b>11:00-11:25</b>	<b>Progress with HIV Vaccine Development</b> <i>Shan Lu, UMASS Chan Medical School</i>	<b>Advancing Vectored Vaccine Design and Manufacturing Platforms for Pandemic Preparedness</b> <i>Amine Kamen, McGill University</i>	
<b>11:25-11:40</b>	<b>First-in-Human, Germline Targeting HIV Vaccine B Cell Receptor Analysis Adapting 10X Technology</b> <i>WeiWei Wu, NIAID, National Institutes of Health</i>	<b>Anti-NA and -HA Serum Confers Limited Inter-Lineage Cross Protection Against Recent Influenza B Vaccine Strains</b> <i>Xavier Saelens, VIB-UGent Center for Medical Biotechnology</i>	
<b>11:40-11:55</b>	<b>Assessing the Frequency of Naive B Cells Potentially Capable of Producing Broad Neutralizing Antibodies for HIV</b> <i>Flavio Matassoli, VRC, NIAID, National Institutes of Health</i>	<b>Establishing Serological Correlates of Vaccine Protection against Emerging Diseases Using WHO International Standards as Calibrants</b> <i>Neil Almond - Medicines and Healthcare Products Regulatory Agency (NIBSC)</i>	
<b>11:55-12:10</b>	<b>Elicitation of Cross-Neutralizing Antibodies to the HIV-1 Envelope Glycoprotein</b> <i>Richard Wyatt, The Scripps Research Institute</i>	<b>Vaccine-Induced Antibodies to Four Distinct Epitopes on gC2 Correlate with Protection from Lethal HSV-2 Challenge in Mice</b> <i>Lauren Hook, University of Pennsylvania Perelman School of Medicine</i>	
<b>12:10-12:25</b>	<b>HIV-1 gp120 Envelope Protein Adjuvanted with Army Liposome Formulation ALFQ Induces Potent and Durable Antigen-Specific Humoral and Cellular Immune Responses in Nonhuman Primates</b> <i>Mangala Rao, Walter Reed Army Institute of Research</i>	<b>B Cell ImmunoSpot® Assays Enable Detailed Assessment of Antigen-Reactive B Cell Frequencies, Class Usage and Functional Affinity</b> <i>Greg Kirchenbaum, Cellular Technology Limited</i>	
<b>12:30-14:00</b>	<b>LUNCH</b>		<b>Sponsored by Medicago</b>
<b>14:00-14:25</b>	<b>ISV Paper of the Year Presentation</b> <b>Neutralizing Antibody Vaccine for Pandemic and Pre-Emergent Coronaviruses</b> <i>Kevin Saunders, Duke University</i>		

<b>14:30-15:45</b>	<b>PLENARY SESSION 6: FUTURE OF VACCINOLOGY</b> <b>SESSION CHAIRS: TBC</b>
<b>14:30-14:55</b>	<b>Title: TBC</b> Peter Kwong, <i>Vaccine Research Center, NIAID, National Institutes of Health</i>
<b>14:55-15:20</b>	<b>Medical Imaging as a Tool for Assessing Pathogenesis in Animals</b> Connie Schmaljohn, <i>NIAID, National Institutes of Health</i>
<b>15:20-15:45</b>	<b>Contribution of T Cell Responses to Vaccine Immunogenicity</b> Jennifer Juno, <i>University of Melbourne</i>
<b>15:45-16:15</b>	<b>ISV AWARD CEREMONY AND INTRODUCTION TO 2023 CONGRESS</b>

**End of Program**